Halozyme Therapeutics Inc (HALO)

Total asset turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	810,397	762,509	752,443	685,200	643,040	566,152	478,768	464,176	435,810	457,564	408,802	329,314	267,594	199,556	180,470	164,397	195,992	202,559	181,885	177,939
Total assets	US$ in thousands	1,733,270	1,892,660	1,810,440	1,699,450	1,841,510	1,864,540	1,781,390	1,162,250	1,104,430	1,185,420	1,025,860	966,582	579,924	524,029	526,997	492,353	565,874	370,356	417,830	429,109
Total asset turnover		0.47	0.40	0.42	0.40	0.35	0.30	0.27	0.40	0.39	0.39	0.40	0.34	0.46	0.38	0.34	0.33	0.35	0.55	0.44	0.41

December 31, 2023 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $810,397K ÷ $1,733,270K
= 0.47

The total asset turnover of Halozyme Therapeutics Inc. has exhibited fluctuations over the past eight quarters. The total asset turnover ratio measures the efficiency with which the company generates revenues relative to its total assets.

The trend shows that the total asset turnover ratio has been generally increasing from Q1 2022 to Q4 2023, indicating a positive movement in utilizing its assets to generate sales. This increase implies that the company has been more effective in leveraging its assets to drive revenue growth.

The ratio ranged from 0.27 in Q2 2022 to 0.48 in Q4 2023. Q4 2023 had the highest total asset turnover ratio during the period under review, suggesting that the company was able to generate $0.48 in revenue for every dollar of assets it held in that quarter.

Overall, the increasing trend in total asset turnover reflects improved efficiency in asset utilization, which is a positive indicator for the company's operational performance and potential for revenue growth.